Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
N = 53 inpatients with major depressive disorder have been treated with the reversible, selective MAO-A-inhibitors moclobemide (double-blind versus maprotiline) and brofaromine (open study), respectively. Clinically, significant improvement of depression and an activating profile of action could be observed, typical side effects were sleep disturbances, agitation and weight loss. The neurobiochemical data showed an increase of noradrenaline plasma concentrations under treatment with moclobemide. Visual reaction times improved with antidepressant treatment. MAO-A inhibitors proved to be effective antidepressants in the treatment of hospitalized patients with predominantly endogenous depressions.
Laux
G
G
Department of Psychiatry, University of Würzburg, Federal Republic of Germany.
Classen
W
W
Sofic
E
E
Becker
T
T
Riederer
P
P
Lesch
K P
KP
Struck
M
M
Beckmann
H
H
D001549:Benzamides / Q000627:therapeutic use*; D002395:Catecholamines / Q000097:blood; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D001549:Benzamides; D002395:Catecholamines; D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; C038213:brofaromine; D008995:Monoamine Oxidase; D020912:Moclobemide